Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 26.39
QCOR's Cash to Debt is ranked lower than
53% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. QCOR: 26.39 )
Ranked among companies with meaningful Cash to Debt only.
QCOR' s 10-Year Cash to Debt Range
Min: 0.91  Med: 12.35 Max: No Debt
Current: 26.39
Equity to Asset 0.63
QCOR's Equity to Asset is ranked lower than
56% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. QCOR: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
QCOR' s 10-Year Equity to Asset Range
Min: -0.11  Med: 0.65 Max: 0.95
Current: 0.63
-0.11
0.95
F-Score: 5
Z-Score: 14.52
M-Score: -2.50
WACC vs ROIC
1.99%
199.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 54.73
QCOR's Operating margin (%) is ranked higher than
96% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. QCOR: 54.73 )
Ranked among companies with meaningful Operating margin (%) only.
QCOR' s 10-Year Operating margin (%) Range
Min: -1200  Med: -16.37 Max: 60.45
Current: 54.73
-1200
60.45
Net-margin (%) 36.05
QCOR's Net-margin (%) is ranked higher than
94% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. QCOR: 36.05 )
Ranked among companies with meaningful Net-margin (%) only.
QCOR' s 10-Year Net-margin (%) Range
Min: -1033.33  Med: -18.98 Max: 75.52
Current: 36.05
-1033.33
75.52
ROE (%) 85.24
QCOR's ROE (%) is ranked higher than
99% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. QCOR: 85.24 )
Ranked among companies with meaningful ROE (%) only.
QCOR' s 10-Year ROE (%) Range
Min: -161.22  Med: -13.48 Max: 104.28
Current: 85.24
-161.22
104.28
ROA (%) 47.94
QCOR's ROA (%) is ranked higher than
98% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. QCOR: 47.94 )
Ranked among companies with meaningful ROA (%) only.
QCOR' s 10-Year ROA (%) Range
Min: -98.06  Med: -10.78 Max: 74.84
Current: 47.94
-98.06
74.84
ROC (Joel Greenblatt) (%) 1414.97
QCOR's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. QCOR: 1414.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
QCOR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1642.88  Med: -77.60 Max: 14668.66
Current: 1414.97
-1642.88
14668.66
Revenue Growth (3Y)(%) 94.00
QCOR's Revenue Growth (3Y)(%) is ranked higher than
96% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. QCOR: 94.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
QCOR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -12.2  Med: 32.40 Max: 94.3
Current: 94
-12.2
94.3
EBITDA Growth (3Y)(%) 106.40
QCOR's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. QCOR: 106.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
QCOR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -62.2  Med: 28.80 Max: 117.8
Current: 106.4
-62.2
117.8
EPS Growth (3Y)(%) 106.60
QCOR's EPS Growth (3Y)(%) is ranked higher than
98% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. QCOR: 106.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
QCOR' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.5  Med: 5.00 Max: 106.6
Current: 106.6
-52.5
106.6
» QCOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

QCOR Guru Trades in Q4 2013

John Paulson 731,410 sh (New)
Steven Cohen 520,938 sh (+1525.29%)
Paul Tudor Jones 10,000 sh (+63.93%)
Joel Greenblatt 296,803 sh (+55.43%)
Chuck Royce 48,200 sh (+9.30%)
John Hussman 150,000 sh (unchged)
Paul Tudor Jones 9,500 sh (unchged)
Jim Simons 769,400 sh (-12.04%)
» More
Q1 2014

QCOR Guru Trades in Q1 2014

David Dreman 806 sh (New)
Joel Greenblatt 335,494 sh (+13.04%)
John Hussman 150,000 sh (unchged)
Paul Tudor Jones 35,000 sh (unchged)
John Paulson Sold Out
Paul Tudor Jones 9,200 sh (-8.00%)
Steven Cohen 416,600 sh (-20.03%)
Chuck Royce 32,200 sh (-33.20%)
Jim Simons 445,400 sh (-42.11%)
» More
Q2 2014

QCOR Guru Trades in Q2 2014

John Paulson 2,248,913 sh (New)
Jeremy Grantham 52,200 sh (New)
Prem Watsa 6,500 sh (New)
Richard Perry 1,164,514 sh (New)
Louis Moore Bacon 55,000 sh (New)
Mario Gabelli 7,100 sh (New)
Paul Tudor Jones 35,000 sh (unchged)
Paul Tudor Jones Sold Out
David Dreman Sold Out
Chuck Royce 31,000 sh (-3.73%)
Joel Greenblatt 319,725 sh (-4.70%)
John Hussman 100,000 sh (-33.33%)
Jim Simons 101,600 sh (-77.19%)
» More
Q3 2014

QCOR Guru Trades in Q3 2014

Mario Gabelli Sold Out
Joel Greenblatt Sold Out
Richard Perry Sold Out
Prem Watsa Sold Out
John Hussman Sold Out
John Paulson Sold Out
Jeremy Grantham Sold Out
Chuck Royce Sold Out
Jim Simons Sold Out
Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with QCOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.40
QCOR's P/E(ttm) is ranked higher than
80% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. QCOR: 16.40 )
Ranked among companies with meaningful P/E(ttm) only.
QCOR' s 10-Year P/E(ttm) Range
Min: 6.47  Med: 15.34 Max: 145.71
Current: 16.4
6.47
145.71
Forward P/E 12.76
QCOR's Forward P/E is ranked higher than
80% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. QCOR: 12.76 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.40
QCOR's PE(NRI) is ranked higher than
81% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. QCOR: 16.40 )
Ranked among companies with meaningful PE(NRI) only.
QCOR' s 10-Year PE(NRI) Range
Min: 6.49  Med: 15.36 Max: 102
Current: 16.4
6.49
102
P/B 10.12
QCOR's P/B is ranked lower than
80% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. QCOR: 10.12 )
Ranked among companies with meaningful P/B only.
QCOR' s 10-Year P/B Range
Min: 1.87  Med: 7.46 Max: 24.88
Current: 10.12
1.87
24.88
P/S 5.91
QCOR's P/S is ranked higher than
68% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. QCOR: 5.91 )
Ranked among companies with meaningful P/S only.
QCOR' s 10-Year P/S Range
Min: 1.08  Med: 4.85 Max: 16.53
Current: 5.91
1.08
16.53
PFCF 14.20
QCOR's PFCF is ranked higher than
86% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. QCOR: 14.20 )
Ranked among companies with meaningful PFCF only.
QCOR' s 10-Year PFCF Range
Min: 4.86  Med: 14.04 Max: 83.9
Current: 14.2
4.86
83.9
POCF 13.85
QCOR's POCF is ranked higher than
84% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. QCOR: 13.85 )
Ranked among companies with meaningful POCF only.
QCOR' s 10-Year POCF Range
Min: 4.86  Med: 14.04 Max: 50.75
Current: 13.85
4.86
50.75
EV-to-EBIT 9.97
QCOR's EV-to-EBIT is ranked higher than
81% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. QCOR: 9.97 )
Ranked among companies with meaningful EV-to-EBIT only.
QCOR' s 10-Year EV-to-EBIT Range
Min: -559.3  Med: 6.90 Max: 180.6
Current: 9.97
-559.3
180.6
PEG 0.17
QCOR's PEG is ranked higher than
97% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. QCOR: 0.17 )
Ranked among companies with meaningful PEG only.
QCOR' s 10-Year PEG Range
Min: 0.14  Med: 0.20 Max: 0.49
Current: 0.17
0.14
0.49
Shiller P/E 41.36
QCOR's Shiller P/E is ranked higher than
55% of the 112 Companies
in the Global Biotechnology industry.

( Industry Median: 44.71 vs. QCOR: 41.36 )
Ranked among companies with meaningful Shiller P/E only.
QCOR' s 10-Year Shiller P/E Range
Min: 14.58  Med: 39.84 Max: 202.33
Current: 41.36
14.58
202.33
Current Ratio 3.17
QCOR's Current Ratio is ranked lower than
60% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. QCOR: 3.17 )
Ranked among companies with meaningful Current Ratio only.
QCOR' s 10-Year Current Ratio Range
Min: 0.92  Med: 3.70 Max: 34.75
Current: 3.17
0.92
34.75
Quick Ratio 3.08
QCOR's Quick Ratio is ranked lower than
57% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. QCOR: 3.08 )
Ranked among companies with meaningful Quick Ratio only.
QCOR' s 10-Year Quick Ratio Range
Min: 0.92  Med: 3.24 Max: 34.75
Current: 3.08
0.92
34.75
Days Inventory 69.85
QCOR's Days Inventory is ranked higher than
70% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. QCOR: 69.85 )
Ranked among companies with meaningful Days Inventory only.
QCOR' s 10-Year Days Inventory Range
Min: 18.71  Med: 115.02 Max: 276.31
Current: 69.85
18.71
276.31
Days Sales Outstanding 39.63
QCOR's Days Sales Outstanding is ranked higher than
70% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. QCOR: 39.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
QCOR' s 10-Year Days Sales Outstanding Range
Min: 17.47  Med: 45.27 Max: 173.37
Current: 39.63
17.47
173.37

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.28
QCOR's Dividend Yield is ranked higher than
51% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 1.28 vs. QCOR: 1.28 )
Ranked among companies with meaningful Dividend Yield only.
QCOR' s 10-Year Dividend Yield Range
Min: 0.65  Med: 1.42 Max: 1.9
Current: 1.28
0.65
1.9
Dividend Payout 0.25
QCOR's Dividend Payout is ranked higher than
68% of the 121 Companies
in the Global Biotechnology industry.

( Industry Median: 0.36 vs. QCOR: 0.25 )
Ranked among companies with meaningful Dividend Payout only.
QCOR' s 10-Year Dividend Payout Range
Min: 0.16  Med: 0.22 Max: 0.39
Current: 0.25
0.16
0.39
Yield on cost (5-Year) 1.28
QCOR's Yield on cost (5-Year) is ranked lower than
56% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 1.26 vs. QCOR: 1.28 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
QCOR' s 10-Year Yield on cost (5-Year) Range
Min: 0.65  Med: 1.42 Max: 1.9
Current: 1.28
0.65
1.9
Share Buyback Rate 1.70
QCOR's Share Buyback Rate is ranked higher than
96% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. QCOR: 1.70 )
Ranked among companies with meaningful Share Buyback Rate only.
QCOR' s 10-Year Share Buyback Rate Range
Min: 3  Med: -11.35 Max: -34.5
Current: 1.7

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) 10.00
QCOR's Earnings Yield (Greenblatt) (%) is ranked higher than
95% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. QCOR: 10.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
QCOR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.6  Med: 10.20 Max: 28.7
Current: 10
0.6
28.7
Forward Rate of Return (Yacktman) (%) 95.18
QCOR's Forward Rate of Return (Yacktman) (%) is ranked higher than
99% of the 103 Companies
in the Global Biotechnology industry.

( Industry Median: 13.70 vs. QCOR: 95.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
QCOR' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -47  Med: 1.80 Max: 95.4
Current: 95.18
-47
95.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QPH.Germany,
Questcor Pharmaceuticals, Inc was incorporated in California in September 1992 as Cypros Pharmaceutical Corporation. In November 1999. The Company changed its name to Questcor Pharmaceuticals, Inc. The Company is a biopharmaceutical company focused on providing prescription drugs for central nervous system disorders. It is presently building a core portfolio of both marketed and development-stage products that address significant unmet medical needs. The Company seeks to develop and commercialize its own proprietary products, and is open to a range of partnering concepts in order to leverage its assets and build its portfolio. It markets H.P. Acthar Gel, an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is not indicated for, but is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral, which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. It owns the worldwide rights for Acthar and the U.S. rights for Doral.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK